Docoh
Loading...

BBI Brickell Biotech

Brickell Biotech, Inc. is a clinical-stage pharmaceutical company focused on the development of innovative and differentiated prescription therapeutics for debilitating skin diseases with a focus on its lead asset sofpironium bromide for the treatment of hyperhidrosis. Brickell's executive management team and board of directors bring extensive experience in product development and global commercialization, having served in leadership roles at large global pharmaceutical companies and biotechs that have developed and/or launched successful products, including several that were first-in-class and/or achieved iconic status, such as Cialis®, Taltz®, Gemzar®, Prozac®, Cymbalta® and Juvederm®. Brickell's strategy is to leverage this experience to in-license, acquire, develop and commercialize innovative and differentiated pharmaceutical products that Brickell believes can be successful in the marketplace and transform lives by solving currently unmet patient needs.

Company profile

Ticker
BBI
Exchange
Website
CEO
Robert Brown
Employees
Incorporated
Location
Fiscal year end
Former names
VICAL INC, VICAL, INC.
SEC CIK
IRS number
930948554

BBI stock data

(
)

Calendar

13 May 21
2 Aug 21
31 Dec 21
Quarter (USD)
Mar 21 Dec 20 Sep 20 Jun 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD)
Dec 20 Dec 19 Dec 18 Dec 17
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Cash burn rate (estimated) Burn method: Change in cash Burn method: Operating income/loss Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 34.78M 34.78M 34.78M 34.78M 34.78M 34.78M
Cash burn (monthly) (positive/no burn) (positive/no burn) 3M 2.16M 1.96M 1.61M
Cash used (since last report) n/a n/a 12.3M 8.84M 8.05M 6.6M
Cash remaining n/a n/a 22.48M 25.94M 26.73M 28.18M
Runway (months of cash) n/a n/a 7.5 12.0 13.6 17.5

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
26 Jul 21 Hardy Reginald L Common Stock Buy Aquire P No No 0.6742 100,000 67.42K 448,411
23 Jul 21 McAvoy David R. Common Stock Buy Aquire P No No 0.6697 18,124 12.14K 128,879
23 Jul 21 Hardy Reginald L Common Stock Buy Aquire P No No 0.6623 100,000 66.23K 348,411
14 Jun 21 Lyons Gary A Stock Option Common Stock Grant Aquire A No No 0.9 40,000 36K 40,000
14 Jun 21 Brown Robert Busard Stock Option Common Stock Grant Aquire A No No 0.9 750,000 675K 750,000
14 Jun 21 Chadha Deepak Stock Option Common Stock Grant Aquire A No No 0.9 250,000 225K 250,000

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

13F holders
Current Prev Q Change
Total holders 0 0
Opened positions 0 0
Closed positions 0 0
Increased positions 0 0
Reduced positions 0 0
13F shares
Current Prev Q Change
Total value 0 0
Total shares 0 0
Total puts 0 0
Total calls 0 0
Total put/call ratio
Largest owners
Shares Value Change
Largest transactions
Shares Bought/sold Change

Financial report summary

?
Risks
  • Our business depends on the successful financing, clinical development, regulatory approval, and commercialization of sofpironium bromide.
  • We previously have not conducted a pivotal Phase 3 clinical trial ourselves and may be unable to successfully do so for sofpironium bromide.
  • Clinical drug development for sofpironium bromide is expensive, time-consuming, and uncertain.
  • Use of PROs and gravimetric assessments in sofpironium bromide clinical trials may delay or adversely impact the development of sofpironium bromide gel or clinical trial results or increase our development costs.
  • Sofpironium bromide may cause undesirable side effects or have other unexpected properties that could delay or prevent its regulatory approval, limit the commercial profile of an approved label, or result in post-approval regulatory action.
  • Under our Clinical Supply Agreement with Kaken, our inability to obtain such API from Kaken on a timely basis could have a material adverse impact on our business.
  • Kaken substantially controls the development and commercialization of sofpironium bromide in Japan and certain other Asian countries and may make decisions regarding product development, regulatory strategy, and commercialization that may not be in our best interests. Kaken may be unable to secure an appropriate local business partner (if desirable) and/or obtain approval of the drug in the ex-Japan Asian markets over which it has rights.
  • If we or any partners with which we may collaborate to market and sell sofpironium bromide are unable to achieve and maintain medical insurance coverage and adequate levels of reimbursement for this compound following regulatory approval and usage by patients, our commercial success may be hindered severely.
  • Major public health issues, and specifically the pandemic caused by the spread of COVID-19 and COVID-19 variants, could have an adverse impact on our financial condition and results of operations and other aspects of our business and that of our suppliers, contractors, and business partners.
  • Sofpironium bromide, if approved, will face significant competition and its failure to compete effectively may prevent it from achieving significant market penetration.
  • We may face generic competition for sofpironium bromide, which could expose us to litigation or adversely affect our business, financial condition, operating results, and prospects.
  • We currently have limited marketing capabilities and no sales organization. If we are unable to establish sales and marketing capabilities on our own or through third parties, or are delayed in establishing these capabilities, we will be unable to successfully commercialize our product candidates, if approved, or generate product revenue.
  • Our collaboration with AnGes may prove to be unsuccessful, either because AnGes is unable to timely develop its COVID-19 vaccine candidate, or because we are not able to continue with this alliance for a variety of business, financial, or other reasons.
  • Our business and operations would suffer in the event of system failures, cyber-attacks, or a deficiency in our cyber-security.
  • We may be adversely affected by natural disasters and other catastrophic events and by man-made problems such as war or terrorism or labor disruptions that could disrupt our business operations, and our business continuity and disaster recovery plans may not adequately protect us from a serious disaster.
  • We will need to raise substantial additional financing in the future to fund our operations and/or prepare an NDA submission in the U.S. for sofpironium bromide, which may not be available to us on favorable terms or at all.
  • Our operating results and liquidity needs could be affected negatively by global market fluctuations and economic downturns.
  • Our stock price and volume of shares traded have been and may continue to be highly volatile, and our common stock may continue to be illiquid.
  • Our operating results may fluctuate significantly, which makes our future operating results difficult to predict and could cause our operating results to fall below expectations.
  • We are a “smaller reporting company” and the reduced disclosure and governance requirements applicable to smaller reporting companies may make our common stock less attractive to some investors.
  • If the holders of our company’s stock options and warrants exercise their rights to purchase our common stock, the ownership of our stockholders will be diluted.
  • We may not be able to access the full amounts available under the Purchase Agreement with Lincoln Park, which could prevent us from accessing the capital we need to continue our operations, which could have an adverse effect on our business.
  • Our failure to maintain compliance with The Nasdaq Stock Market LLC’s (“Nasdaq”) continued listing requirements could result in the delisting of our common stock.
  • We do not anticipate paying any dividends in the foreseeable future.
  • Our ability to use our net operating loss carryforwards and other tax assets to offset future taxable income may be subject to certain limitations.
  • We have sponsored or supported and may in the future sponsor or support clinical trials for our product candidates outside the U.S. and Japan, and the FDA, PMDA, and applicable foreign regulatory authorities may not accept data from such trials; in addition, we may not be allowed alone or with local country business partners to obtain regulatory approval for our product candidates without first conducting clinical trials in each of these other countries.
  • We may face product liability exposure, and if successful claims are brought against us, we may incur substantial liability if our insurance coverage for those claims is inadequate.
  • Our employees, independent contractors, principal investigators, other clinical trial staff, consultants, vendors, CROs, and any partners with which we may collaborate may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements.
  • We may be subject to risks related to pre-approval promotion or off-label use, or unauthorized direct-to-consumer advertising, of our product candidates.
  • Healthcare reform measures, including price controls or restricted access, could hinder or prevent the commercial success of our product candidates.
  • We are and may be subject to strict healthcare laws, regulation, and enforcement, and our failure to comply with those laws could expose us to liability or adversely affect our business, financial condition, operating results, and prospects.
  • We incur costs and demands upon management as a result of complying with the laws and regulations affecting public companies.
  • We intend to in-license and acquire product candidates and may engage in other strategic transactions, which could impact our liquidity, increase our expenses, and present significant distractions to our management.
  • Our failure to in-license, acquire, develop, and market successfully additional product candidates or approved products would impair our ability to grow our business.
  • Other than sofpironium bromide, our other product candidates are at the early stages of clinical and regulatory development.
  • We may choose not to continue developing or commercializing any of our early-stage product candidates, or to pursue the AnGes collaboration regarding a COVID-19 vaccine, at any time during development or after approval, which would reduce or eliminate our potential return on investment for those product candidates.
  • We expect to rely on our collaboration with third-party out-license partners for the successful development and commercialization of our product candidates.
  • We rely completely on third-party contractors to supply, manufacture, and distribute clinical drug supplies for our product candidates, including certain sole-source suppliers and manufacturers; we intend to rely on third parties for commercial supply, manufacturing, and distribution if any of our product candidates receive regulatory approval; and we expect to rely on third parties for supply, manufacturing, and distribution of preclinical, clinical, and commercial supplies of any future product candidates.
  • Manufacturing and supply of the APIs and other substances and materials used in our product candidates and finished drug products is a complex and technically challenging undertaking, and there is potential for failure at many points in the manufacturing, testing, quality control and assurance, and distribution supply chain, as well as the potential for latent defects after products have been manufactured and distributed.
  • We may not be able to obtain, maintain or enforce global patent rights or other intellectual property rights that cover sofpironium bromide and related technologies (and any other product candidates) that are of sufficient breadth and term.
  • We may not be able to protect our intellectual property rights throughout the world.
  • Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment, and other requirements imposed by governmental patent and similar agencies, and our patent protection could be reduced or eliminated for noncompliance with these requirements.
  • If we fail to comply with our obligations under our intellectual property license agreements, we could lose license rights that are important to our business. Additionally, these agreements may be subject to disagreement over contract interpretation, which could narrow the scope of our rights to the relevant intellectual property or technology or increase our financial or other obligations to our licensors.
  • We may be subject to claims that our employees, officers, directors, advisors, consultants, or independent contractors have wrongfully used or disclosed to us alleged trade secrets or other confidential and proprietary information of their former employers or their former or current partners or customers.
  • Provisions of Delaware law and our restated certificate of incorporation and amended and restated bylaws may discourage another company from acquiring us and may prevent attempts by our stockholders to replace or remove our current management.
  • If we fail to attract and retain management and other key personnel and directors, we may be unable to continue to successfully develop or commercialize our product candidates or otherwise implement our business plan.
Management Discussion
  • Revenue decreased by $1.0 million for the three months ended March 31, 2021, compared to the three months ended March 31, 2020. Revenue in 2021 consisted of royalty revenue recognized related to sales of ECCLOCK® in Japan by Kaken, while revenue in 2020 was driven by collaboration revenue recognized for research and development activities under the Kaken Agreement pursuant to which Kaken provided to us
  • research and development funding. The decrease in revenue recognized was primarily attributable to our Phase 3 open-label long-term safety study of sofpironium bromide gel and other ancillary clinical studies that were concluded or winding down by the end of the first quarter of 2020. Conducting these studies was the basis for revenue recognition over time, through the third quarter of 2020, of a $15.6 million research and development payment received from Kaken in the second quarter of 2018. Beginning during the three months ended December 31, 2020, and continuing in the three months ended March 31, 2021, pursuant to the Kaken Agreement, we recognized royalty revenue earned on a percentage of net sales of sofpironium bromide in Japan, and we expect to continue to recognize such royalties on Kaken’s net sales going forward. Despite recognizing such royalty revenue, we did not receive any cash related to such royalties because Kaken instead offset amounts we owed it under the Clinical Supply Agreement.
  • Research and development expenses increased by $3.4 million for the three months ended March 31, 2021, compared to the three months ended March 31, 2020, which was primarily due to an increase in clinical costs related to sofpironium bromide. We began incurring greater research and development costs upon the initiation of our Phase 3 Cardigan Studies in the fourth quarter of 2020. Our Phase 3 open-label, long-term safety study of sofpironium bromide gel and other ancillary clinical studies were concluded or winding down by the end of the first quarter of 2020.
Content analysis
?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. senior Avg
New words: acclimated, aka, Blair, blurred, body, carefully, carryforward, cheaper, China, conventional, cyber, cybersecurity, dry, easily, effort, erythema, ESPP, expended, flexibility, formulation, gradual, hesitation, incidence, irritation, Korea, malware, marked, maximize, mild, moderate, monetization, mouth, National, occupancy, pain, phishing, preying, PRO, prohibitory, ratio, refill, remote, retention, salesforce, Secretary, South, strict, surpassed, thermoregulation, track, transient, Unaudited, understand, uneven, unsuccessful, urinary, Vice, vision, visit, vital, website, William, withdrawn
Removed: accounted, accretion, adjusted, age, amortized, analyzed, anticholinergic, assistance, assuming, ASU, bearing, bifurcated, borrowed, borrowing, bundled, calculating, Chairperson, charge, Chief, claiming, classification, combined, constrained, converted, derivative, determinable, disability, discount, discounted, discrimination, disposition, dispute, distinguish, Distinguishing, embedded, evolved, exhibit, expedient, feature, firm, fiscal, forum, gender, headcount, Hedging, identification, implicit, incremental, input, investor, Journal, judged, lender, licensee, measurement, merged, nonrefundable, outbreak, Patricia, PK, practical, prevalent, Prime, Prom, proportionately, readily, real, realization, realized, recapitalization, Reimbursable, remeasured, remeasurement, Reorganization, repaid, repayment, representative, resolved, resolving, reverse, settlement, settling, Street, sum, surviving, temporary, thermal, tranche, unaccreted, unconstrained, unrealized, unspecified, vendor, Victory, Walker, Wall, wrongful